JP2009256374A5 - - Google Patents

Download PDF

Info

Publication number
JP2009256374A5
JP2009256374A5 JP2009181759A JP2009181759A JP2009256374A5 JP 2009256374 A5 JP2009256374 A5 JP 2009256374A5 JP 2009181759 A JP2009181759 A JP 2009181759A JP 2009181759 A JP2009181759 A JP 2009181759A JP 2009256374 A5 JP2009256374 A5 JP 2009256374A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
stem cells
nitric oxide
oxide donor
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009181759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009256374A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009256374A publication Critical patent/JP2009256374A/ja
Publication of JP2009256374A5 publication Critical patent/JP2009256374A5/ja
Pending legal-status Critical Current

Links

JP2009181759A 2002-01-04 2009-08-04 疾患および損傷の処置のための一酸化窒素ドナー Pending JP2009256374A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34547802P 2002-01-04 2002-01-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003557275A Division JP4545440B2 (ja) 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー

Publications (2)

Publication Number Publication Date
JP2009256374A JP2009256374A (ja) 2009-11-05
JP2009256374A5 true JP2009256374A5 (cg-RX-API-DMAC7.html) 2010-09-16

Family

ID=23355218

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003557275A Expired - Fee Related JP4545440B2 (ja) 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー
JP2009181759A Pending JP2009256374A (ja) 2002-01-04 2009-08-04 疾患および損傷の処置のための一酸化窒素ドナー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003557275A Expired - Fee Related JP4545440B2 (ja) 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー

Country Status (9)

Country Link
US (2) US20050143388A1 (cg-RX-API-DMAC7.html)
EP (1) EP1469852A4 (cg-RX-API-DMAC7.html)
JP (2) JP4545440B2 (cg-RX-API-DMAC7.html)
CN (1) CN1638775A (cg-RX-API-DMAC7.html)
AU (1) AU2003210447B2 (cg-RX-API-DMAC7.html)
CA (1) CA2471147C (cg-RX-API-DMAC7.html)
IL (1) IL162850A0 (cg-RX-API-DMAC7.html)
WO (1) WO2003056899A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200405507B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909793A2 (de) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von erkrankungen oder gesundheitsstörungen, sowie abgabesysteme für dieselben
CA2629463A1 (en) * 2005-11-14 2008-02-21 Scott A. Small Imaging correlates of neurogenesis with mri
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
WO2008144061A2 (en) * 2007-05-18 2008-11-27 Vivus, Inc. Novel combinations comprising a phosphodiesterase-5 inhibitor and their use
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
WO2009059271A1 (en) * 2007-11-02 2009-05-07 University Of Miami Diagnosis and treatment of cardiac disorders
US9469637B2 (en) 2012-04-25 2016-10-18 Takeda Pharmaceutical Company Limited Nitrogenated heterocyclic compound
WO2014010732A1 (ja) 2012-07-13 2014-01-16 武田薬品工業株式会社 複素環化合物
DK2961741T3 (en) * 2013-03-01 2017-07-03 Fund Para La Investig Medica Aplicada Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
US10297661B2 (en) * 2017-06-30 2019-05-21 Taiwan Semiconductor Manufacturing Co., Ltd. High voltage resistor device
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187086A1 (en) * 1994-04-15 1995-10-26 Masaomi Iyo A pharmaceutical composition for therapeutically treating tardive dyskinesia and uses therof
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
CA2373808C (en) * 1999-05-14 2011-04-19 Henry Ford Health System Bone marrow transplantation for treatment of central nervous system damage
ATE408402T1 (de) * 1999-06-14 2008-10-15 Ford Henry Health System Stickstoffmonoxid-donoren zum induzieren von neurogenese
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
US6271228B1 (en) 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
EP1355669B1 (en) * 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training

Similar Documents

Publication Publication Date Title
JP2009256374A5 (cg-RX-API-DMAC7.html)
JP2012255026A5 (cg-RX-API-DMAC7.html)
JP2010222367A5 (cg-RX-API-DMAC7.html)
RU2600440C3 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
JP2013542247A5 (cg-RX-API-DMAC7.html)
JP2010535814A5 (cg-RX-API-DMAC7.html)
JP2012500090A5 (cg-RX-API-DMAC7.html)
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
JP2012530141A5 (cg-RX-API-DMAC7.html)
WO2010062688A3 (en) Dosage form for insertion into the mouth
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
JP2012517449A5 (cg-RX-API-DMAC7.html)
NZ593475A (en) Calcium salts for reducing exhalation of infectious bioaerosol particles
RU2014142025A (ru) Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
MA32406B1 (fr) Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens
JP2012508256A5 (cg-RX-API-DMAC7.html)
JP2012518646A5 (cg-RX-API-DMAC7.html)
JP2007238598A5 (cg-RX-API-DMAC7.html)
DK1746980T3 (da) Farmaceutisk doseringsform omfattende pellets såvel som deres fremstillingsfremgangsmåde
JP2013543518A5 (cg-RX-API-DMAC7.html)
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
JP2002537232A5 (cg-RX-API-DMAC7.html)
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
JP2011516572A5 (cg-RX-API-DMAC7.html)